NCT06175845Recruiting
Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma
Radiofrequency Ablation Via Catheter and Transpapillary Access in Patients With Cholangiocarcinoma
Source: ClinicalTrials.gov · Last updated 9 Sept 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn about radiofrequency ablation in patients with unresectable bile duct cancer who receive systemic chemotherapy and bile duct stenting. The main questions it aims to answer are: * Does radiofrequency ablation of tumorous bile duct occlusion reduce risk of complications in these patients (eg stent dysfunction, delay of chemotherapy, infections etc)? * Is radiofrequency ablation safe in these patients? All participants will receive standard treatment with systemic chemotherapy and bile duct stenting. Researchers will compare two groups (one group will receive additional radiofrequency ablation, the other not).
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 130 (estimated)
- First submitted
- 25 Nov 2023
- Start date
- 30 Aug 2024
- Primary completion date
- Jul 2027
- Lead sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06175845
What you commit to
- Study type: Interventional
- Planned participants: 130
- From 30 Aug 2024 to the primary completion date, Jul 2027
- 9 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Unresectable perihilar and/or ductal CCA with bile duct stenting and palliative systemic therapy as indicated by the local Multidisciplinary Team (MDT)
- Written informed consent
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Age ≥18 years
- Eligibility for palliative systemic therapy based on clinical and laboratory parameters (except hyperbilirubinemia) as determined by the local MDT
- No prior radiofrequency ablation (RFA) for CCA
- No repeated bile duct stenting in the past 3 months (trial inclusion is possible upon first stent replacement or initial stent placement within past 3 months)
- No concomitant disease or malignancy interfering with the study procedure or efficacy outcome measures, particularly no severe or uncontrolled cardiovascular disease (congestive heart failure NYHA III or IV, unstable angina pectoris, myocardial infarction within ≤3 months, significant arrhythmias) and no psychiatric disorders precluding understanding of information of trial related topics and giving informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (9)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Charite Coordinator of this site? Confirm its status | Berlin | Germany | Recruiting |
| University Medical Center Coordinator of this site? Confirm its status | Bonn | Germany | Recruiting |
| Clinic Chemnitz Coordinator of this site? Confirm its status | Chemnitz | Germany | Recruiting |
| University Clinic Coordinator of this site? Confirm its status | Essen | Germany | Recruiting |
| University Medical Center Hamburg-Eppendorf Coordinator of this site? Confirm its status | Hamburg | Germany | Recruiting |
| Medical School Hannover Coordinator of this site? Confirm its status | Hanover | Germany | Recruiting |
| University Clinic Coordinator of this site? Confirm its status | Heidelberg | Germany | Recruiting |
| UKSH Coordinator of this site? Confirm its status | Lübeck | Germany | Recruiting |
| Clinic Ulm Coordinator of this site? Confirm its status | Ulm | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.